<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2025</Year>
        <Month>01</Month>
        <Day>21</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Minimal Residual Disease in Acute Lymphoblastic Leukaemia and Its Relationship with Other Prognostic Factors</title>
    <FirstPage>37</FirstPage>
    <LastPage>42</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Chinmayee</FirstName>
        <LastName>Agrawal</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, Ramaiah Medical College, Bengaluru, India</affiliation>
      </Author>
      <Author>
        <FirstName>Sai</FirstName>
        <LastName>Boppana</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, NRI Medical College and Hospital, Mangalagiri, Andhra Pradesh, India</affiliation>
      </Author>
      <Author>
        <FirstName>Santhosh</FirstName>
        <LastName>Devdas</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, Ramaiah Medical College, Bengaluru, India</affiliation>
      </Author>
      <Author>
        <FirstName>Vinayak</FirstName>
        <LastName>Maka</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, Ramaiah Medical College, Bengaluru, India</affiliation>
      </Author>
      <Author>
        <FirstName>Nalini</FirstName>
        <LastName>Kilara</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, Ramaiah Medical College, Bengaluru, India</affiliation>
      </Author>
      <Author>
        <FirstName>Swaratika</FirstName>
        <LastName>Majumdar</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, Ramaiah Medical College, Bengaluru, India</affiliation>
      </Author>
      <Author>
        <FirstName>Rasmi</FirstName>
        <LastName>Palassery</LastName>
        <affiliation locale="en_US">Department of Medical Oncology, Ramaiah Medical College, Bengaluru, India</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>10</Month>
        <Day>10</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>02</Month>
        <Day>27</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Minimal Residual Disease (MRD) assessment is crucial for directing treatment decisions in Acute Lymphoblastic Leukemia (ALL). In low- and middle-income countries, limited resources can present challenges to implementing MRD-guided therapy intensification for ALL. The study attempted to assess the relationship between MRD and other prognostic factors in ALL, focusing on treatment outcomes and disease progression.
&#xD;

Materials and Methods: A retrospective observational study was conducted at Ramaiah Medical College and Hospital in Bengaluru, examining patient data from January 2021 to December 2021. MRD status was determined post-induction using flow cytometry. Patients were classified into various groups based on factors such as type of ALL (B-cell or T-cell), NCI risk status (standard or high), cytogenetic risk (favorable, poor, or intermediate), CNS status, prednisone response, and MRD levels at the end of induction.
&#xD;

Results: Out of 72 patients, 25% were MRD-positive, with a male: female ratio of 2.13:1. B-ALL was diagnosed in 49 patients and T-ALL in 23, with 75% categorized as high-risk by NCI criteria. Cytogenetic analysis revealed a diverse profile (23.61% PR, 48.61% IR, 27.78% FR), and 58.33% exhibited a good prednisone response (GPR). At the end of the induction phase, 25% tested positive for MRD, with B-ALL showing a lower MRD rate at 15.2%. Age and NCI risk status significantly influenced MRD outcomes, with 75% of participants classified as high-risk.
&#xD;

Conclusion: This study demonstrates a significant association between MRD positivity and factors such as age, NCI risk status, and B-ALL diagnosis, underscoring the complex interaction of these variables in predicting treatment outcomes for ALL patients.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2095</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2095/1064</pdf_url>
  </Article>
</Articles>
